cyclophosphamide (low-dose)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for cyclophosphamide (low-dose), covering 2020-10-27 to 2022-03-31. Get the full timeline:
Most recent: Clinical Trial Update: Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors [Phase 2]